Thursday, Adial Pharmaceuticals Inc (NASDAQ:ADIL) said it has completed a pharmacokinetics (PK) study of AD04 for Alcohol Use ...

Confirmed relative bioavailability to the reference standard, dose proportional increases in pharmacokinetic exposure, and no food effectMarks ...

Adial Pharmaceuticals (ADIL) announced that it has completed a pharmacokinetics, PK, study of AD04, the Company’s lead investigational genetically targeted, serotonin-3 receptor antagonist, and ...

BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company ...

US based company Intelligent Bio Solutions has released “strong initial results” from a pharmacokinetic (PK) study and is one ...

Single oral administration of SPM-0404 in vivo penetrates into the CNS of rats and non-human primates with acceptable CNS pharmacokinetics (PK) and systemic whole-body PK in both species. A 100% ...

The findings of these research were presented at The Union World Conference on Lung Health in Bali, Indonesia. One of them is ...

Leading epigenome editing company Tune Therapeutics announced today that it has received clinical trial application (CTA) approval from the New Zealand Medicines and Medical Devices Safety Authority ...

The rise of antibody therapeutics is transforming drug discovery, providing highly specific treatments for complex diseases ...

Company remains on track for first subject treated in pivotal, adaptive Phase 3 clinical trial (the "MIRACLE" trial) in the first quarter of 2025 ...

帕金森病（Parkinson disease，PD）是一种常见的中老年神经系统退行性疾病，因脑内多巴胺的减少、进而导致多巴胺与乙酰胆碱之间平衡被打破进而出现手抖、肢体僵硬、动作迟缓、姿势步态异常等运动症状及睡眠障碍、嗅觉障碍等非运动症状。

SAIHEAT Limited (f/k/a SAI.TECH Global Corporation) ("SAIHEAT” or the "Company”) (NASDAQ: SAIH, SAITW) is pleased to unveil the SAIHEAT BASE PLAN 2029, an ambitious initiative delivering integrated ...